v3.26.1
Condensed Consolidated Statements of Stockholders’ Equity (Deficit) (Unaudited) - USD ($)
Total
Series A Convertible Preferred Stock
Common stock
Additional paid-in capital
Accumulated other comprehensive loss
Accumulated deficit
Beginning balance (in shares) at Dec. 31, 2024   0 8,700,386      
Beginning balance at Dec. 31, 2024 $ (6,012,089) $ 0 $ 870 $ 169,705,480 $ (428,809) $ (175,289,630)
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Stock-based compensation 377,357     377,357    
Issuance of common stock, net of issuance costs (in shares)     150,000      
Issuance of common stock, net of issuance costs 436,248   $ 15 436,233    
Net loss (4,378,307)         (4,378,307)
Foreign currency translation adjustments 13,090       13,090  
Ending balance (in shares) at Mar. 31, 2025   0 8,850,386      
Ending balance at Mar. 31, 2025 (9,563,701) $ 0 $ 885 170,519,070 (415,719) (179,667,937)
Beginning balance (in shares) at Dec. 31, 2024   0 8,700,386      
Beginning balance at Dec. 31, 2024 (6,012,089) $ 0 $ 870 169,705,480 (428,809) (175,289,630)
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Net loss (8,394,790)          
Foreign currency translation adjustments 25,983          
Ending balance (in shares) at Jun. 30, 2025   0 9,030,386      
Ending balance at Jun. 30, 2025 (12,733,260) $ 0 $ 903 171,353,083 (402,826) (183,684,420)
Beginning balance (in shares) at Mar. 31, 2025   0 8,850,386      
Beginning balance at Mar. 31, 2025 (9,563,701) $ 0 $ 885 170,519,070 (415,719) (179,667,937)
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Stock-based compensation 359,018     359,018    
Issuance of common stock, net of issuance costs (in shares)     180,000      
Issuance of common stock, net of issuance costs 475,013   $ 18 474,995    
Net loss (4,016,483)         (4,016,483)
Foreign currency translation adjustments 12,893       12,893  
Ending balance (in shares) at Jun. 30, 2025   0 9,030,386      
Ending balance at Jun. 30, 2025 $ (12,733,260) $ 0 $ 903 171,353,083 (402,826) (183,684,420)
Beginning balance (in shares) at Dec. 31, 2025 14,499,502 0 14,499,502      
Beginning balance at Dec. 31, 2025 $ 2,842,634 $ 0 $ 1,450 191,951,711 (421,623) (188,688,904)
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Stock-based compensation 455,064     455,064    
Issuance of Series A Convertible Preferred Stock and warrants in connection with Regulation A financing, net of issuance costs (in shares)   65,640        
Issuance of Series A Convertible Preferred Stock and warrants in connection with Regulation A financing, net of issuance costs 297,213 $ 656   296,557    
Issuance of common stock, net of issuance costs (in shares)     60,000      
Issuance of common stock, net of issuance costs 94,887   $ 6 94,881    
Net loss (2,999,889)         (2,999,889)
Foreign currency translation adjustments 44,542       44,542  
Ending balance (in shares) at Mar. 31, 2026   65,640 14,559,502      
Ending balance at Mar. 31, 2026 $ 734,451 $ 656 $ 1,456 192,798,213 (377,081) (191,688,793)
Beginning balance (in shares) at Dec. 31, 2025 14,499,502 0 14,499,502      
Beginning balance at Dec. 31, 2025 $ 2,842,634 $ 0 $ 1,450 191,951,711 (421,623) (188,688,904)
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Net loss (5,982,662)          
Foreign currency translation adjustments $ 46,768          
Ending balance (in shares) at Jun. 30, 2026 15,169,502 75,900 15,169,502      
Ending balance at Jun. 30, 2026 $ (560,100) $ 759 $ 1,517 194,484,046 (374,856) (194,671,566)
Beginning balance (in shares) at Mar. 31, 2026   65,640 14,559,502      
Beginning balance at Mar. 31, 2026 734,451 $ 656 $ 1,456 192,798,213 (377,081) (191,688,793)
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Stock-based compensation 286,602     286,602    
Issuance of Series A Convertible Preferred Stock and warrants in connection with Regulation A financing, net of issuance costs (in shares)   270,260        
Issuance of Series A Convertible Preferred Stock and warrants in connection with Regulation A financing, net of issuance costs 1,232,695 $ 2,703   1,229,992    
Conversion of Series A Preferred Stock into common stock (in shares)   (260,000) 520,000      
Conversion of Series A Preferred Stock into common stock 0 $ (2,600) $ 52 2,548    
Issuance of common stock, net of issuance costs (in shares)     90,000      
Issuance of common stock, net of issuance costs 166,700   $ 9 166,691    
Net loss (2,982,773)         (2,982,773)
Foreign currency translation adjustments $ 2,225       2,225  
Ending balance (in shares) at Jun. 30, 2026 15,169,502 75,900 15,169,502      
Ending balance at Jun. 30, 2026 $ (560,100) $ 759 $ 1,517 $ 194,484,046 $ (374,856) $ (194,671,566)